GT Biopharma Inc (NASDAQ:GTBP) — Market Cap & Net Worth
Market Cap & Net Worth: GT Biopharma Inc (GTBP)
GT Biopharma Inc (NASDAQ:GTBP) has a market capitalization of $11.56 Million ($11.56 Million) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #26774 globally and #5563 in its home market, demonstrating a 4009.54% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying GT Biopharma Inc's stock price $11.63 by its total outstanding shares 36062904 (36.06 Million). Also see how large is GT Biopharma Inc's balance sheet for a full breakdown of the balance sheet.
GT Biopharma Inc Market Cap History: 2015 to 2026
GT Biopharma Inc's market capitalization history from 2015 to 2026. Data shows change from $17.66 Trillion to $419.41 Million (-63.18% CAGR). Also see how efficiently does GT Biopharma Inc generate cash for how efficiently the company converts equity into cash flow.
Index Memberships
GT Biopharma Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.67 Trillion | 0.00% | #753 of 976 |
|
NASDAQ Composite
IXIC
|
$41.95 Trillion | 0.00% | #2464 of 3165 |
Weight: GT Biopharma Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
GT Biopharma Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how GT Biopharma Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check GT Biopharma Inc (GTBP) stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
3031286.10x
GT Biopharma Inc's market cap is 3031286.10 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $81.84 Billion | $27.00K | -$144.17 Million | 3031286.10x | N/A |
Competitor Companies of GTBP by Market Capitalization
Companies near GT Biopharma Inc in the global market cap rankings as of September 18, 2026. Review GTBP goodwill-adjusted equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to GT Biopharma Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #185 globally with a market cap of $130.87 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #337 globally with a market cap of $79.84 Billion USD.
- CSL Ltd (AU:CSL): Ranked #455 globally with a market cap of $60.95 Billion USD ( AU$86.14 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #504 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #185 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.87 Billion | $516.34 |
| #337 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.84 Billion | $789.45 |
| #455 | CSL Ltd | AU:CSL | $60.95 Billion | AU$177.56 |
| #504 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $158.07 |
GT Biopharma Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, GT Biopharma Inc's market cap moved from $17.66 Trillion to $ 419.41 Million, with a yearly change of -63.18%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $419.41 Million | +1381.15% |
| 2025 | $28.32 Million | -74.26% |
| 2024 | $109.99 Million | -60.13% |
| 2023 | $275.88 Million | -71.21% |
| 2022 | $958.23 Million | -70.96% |
| 2021 | $3.30 Billion | -57.69% |
| 2020 | $7.80 Billion | +423.46% |
| 2019 | $1.49 Billion | -87.54% |
| 2018 | $11.95 Billion | -85.39% |
| 2017 | $81.84 Billion | -84.08% |
| 2016 | $514.24 Billion | -97.09% |
| 2015 | $17.66 Trillion | -- |
End of Day Market Cap According to Different Sources
On Sep 18th, 2026 the market cap of GT Biopharma Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $11.56 Million USD |
| MoneyControl | $11.56 Million USD |
| MarketWatch | $11.56 Million USD |
| marketcap.company | $11.56 Million USD |
| Reuters | $11.56 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About GT Biopharma Inc
GT Biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of immuno-oncology products based on its Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) platforms. It develops GTB-3650, which is in phase 1 trials that target CD33 on the surface of myeloid leukemias and an agonistic camelid; GTB-5550, tha… Read more